睡眠障碍与疗法杂志
开放获取

抽象的

Topical Magnesium- Coordinated Cannabidiolic Acid (CBDA) for the Treatment of Restless Leg Syndrome

Debra Kimless, Thomas Piccariello, Jabari Byrd

Topical Magnesium-Coordinated Cannabidiolic Acid (CBDA) for the Treatment of Restless Leg Syndrome Restless Leg Syndrome (RLS) is multifactorial disease state with many different potential pathophysiological mechanisms, which includes iron deficiency, dysfunctions from the cerebral cortex and spinal cord to mechanosensitive channels at the musculoskeletal periphery. Most therapeutic agents effectiveness focuses on the central nervous system (e.g., dopaminergic drugs) or Renshaw cells. There are virtually no effective therapeutic agents that are focused on the periphery. We hypothesize that treatment for RLS can focus on the peripheral musculoskeletal component of the disease, more specifically the mechanosensitive channels such as Piezo 2 and TRPA1. We conducted an open-label IRB-approved clinical trial using a proprietary topical preparation of our magnesium-coordinated CBDA to explore the responses to this novel treatment modality. We found a statistically and clinically significant improvement in restless leg symptoms and without any reported adverse effects.